Ototoxicity after platinum-based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Melanotic neuroectodermal tumor of infancy (MNTI) is a rare infantile tumor that originates from mesenchymal-neuroectodermal cells, the treatment of which uses platinum derivatives that can affect hearing loss. The present study evaluated the long-term effects of ototoxicity following chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10-year-old patient after surgical removal of a MNTI tumor at the age of 8 months. Audiometric tests (high-frequency tonal audiometry, speech audiometry, speech acoustics, tympanometry and absorbance measurements) were performed during a 10-year follow-up after receiving chemotherapy. Hearing disorders in the high-frequency range (6,000 to 16,000 Hz range) were demonstrated for both ears, indicating that these may be the long-term effects of chemotherapy with use of platinum compounds during the treatment of infants.

Cite

CITATION STYLE

APA

Hojan-Jezierska, D., Chomiak, A., Czopor, A., Matthews-Kozanecka, M., Majewska, A., Urbaniak-Olejnik, M., & Matthews-Brzozowska, T. (2020). Ototoxicity after platinum-based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy. Oncology Letters, 19(5), 3411–3416. https://doi.org/10.3892/ol.2020.11447

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free